Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.

Anne Julienne GenuinoUsa ChaikledkaewAnna Melissa GuerreroThanyanan ReungwetwattanaAmmarin Thakkinstian

Published in: BMC health services research (2019)

At its current cost, 1 year of adjuvant trastuzumab therapy compared to standard chemotherapy alone for HER2-positive EBC does not represent value for money in the Philippines. Its current cost will have to significantly lower down by one-half to achieve cost-effectiveness.

Keyphrases

early stage
epidermal growth factor receptor
sentinel lymph node
metastatic breast cancer
locally advanced
young adults
bone marrow
neoadjuvant chemotherapy